

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Hematology</b>				
Sickle cell disease	Nuclear receptor subfamily 2 group C member 1 (NR2C1; TR2); NR2C2 (TR4)	<p>Studies in mice suggest upregulating TR2 and/or TR4 could help treat sickle cell disease. In a mouse model of sickle cell disease, artificially high expression of TR2 and TR4 in the blood reduced anemia and organ damage compared with normal TR2 and TR4 expression. Next steps include screening for drugs that modulate TR2 and/or TR4 activity.</p> <p><i>SciBX</i> 4(44); doi:10.1038/scibx.2011.1237 Published online Nov. 10, 2011</p>	Patent application filed; available for licensing	<p>Campbell, A.D. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Oct. 31, 2011; doi:10.1073/pnas.1104964108</p> <p><b>Contact:</b> James Douglas Engel, University of Michigan Medical School, Ann Arbor, Mich. e-mail: <a href="mailto:engel@umich.edu">engel@umich.edu</a></p> <p><b>Contact:</b> Osamu Tanabe, same affiliation as above e-mail: <a href="mailto:otanabe@umich.edu">otanabe@umich.edu</a></p>